1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,660 | 0,700 | 11:31 | |
| 0,670 | 0,695 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | MaxCyte sees Q4 core revenue between $6.6M and $6.7M | 6 | Seeking Alpha | ||
| 12.01. | MaxCyte, Inc: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results | 109 | GlobeNewswire (Europe) | ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery... ► Artikel lesen | |
| MAXCYTE Aktie jetzt für 0€ handeln | |||||
| 19.11.25 | MaxCyte stellt auf Stephens-Konferenz Neuausrichtung | 1 | Investing.com Deutsch | ||
| 13.11.25 | MAXCYTE, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.25 | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 13.11.25 | MaxCyte outlines $17M-$19M annualized savings through restructuring while reiterating SPL revenue guidance | 2 | Seeking Alpha | ||
| 12.11.25 | MaxCyte CFO to step down in first half of 2026 | 2 | Seeking Alpha | ||
| 12.11.25 | MaxCyte CFO Douglas Swirsky to step down in first half of 2026 | 4 | Investing.com | ||
| 12.11.25 | MaxCyte, Inc: MaxCyte Announces Planned CFO Transition in 2026 | 126 | GlobeNewswire (Europe) | ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 11.11.25 | Insights into MaxCyte's Upcoming Earnings | 1 | Benzinga.com | ||
| 05.11.25 | MAXCYTE, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 05.11.25 | MaxCyte, Inc: MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance | 183 | GlobeNewswire (Europe) | MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November... ► Artikel lesen | |
| 08.10.25 | MaxCyte, Inc: MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 06.10.25 | MaxCyte, Inc: MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors | 325 | GlobeNewswire (Europe) | ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and... ► Artikel lesen | |
| 22.09.25 | MaxCyte announces 34% workforce reduction to cut costs | 1 | Seeking Alpha | ||
| 22.09.25 | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09.25 | MaxCyte, Inc: MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability | 256 | GlobeNewswire (Europe) | ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 26.08.25 | MAXCYTE, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,017 | -21,43 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,339 | +1,14 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| IMMATICS | 7,620 | -6,22 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| ALDEYRA | 4,700 | +0,38 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| MEDIFAST | 9,172 | -4,46 % | Medifast: OPTAVIA Premieres Second Docuseries Episode "Health by Design: Spain" Exploring Metabolic Health and Longevity | Thousands of Independent Coaches Gather Nationwide to Discuss Solutions to America's Metabolic Health Crisis Medifast (NYSE: MED), the health and wellness company known for its science-backed... ► Artikel lesen | |
| PHARMING | 1,390 | +1,46 % | Pharming Group N.V.: Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day | Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,747 | -3,29 % | Coherus Biosciences stock gains on JNJ clinical supply agreement | ||
| ORUKA THERAPEUTICS | 26,000 | -3,70 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| INNOVIVA | 18,300 | -1,08 % | FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea | ||
| ARMATA PHARMACEUTICALS | 6,700 | +0,75 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia | FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study
First bacteriophage company to advance a clinical candidate... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,500 | -1,69 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| DBV TECHNOLOGIES | 3,520 | -3,43 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 | Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative... ► Artikel lesen | |
| LIQUIDIA | 35,660 | -1,98 % | Liquidia Technologies, Inc.: Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update | Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,700 | +2,92 % | SIGA Technologies - Fundamentals intact amid several moving parts | Q325 was a quieter quarter for SIGA following strong Q2 sales, although this was not unexpected given its contract-driven model and inherent revenue lumpiness. No product sales were recorded, with total... ► Artikel lesen |
MAXCYTE INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,685 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAXCYTE INC finden Sie auf Wallstreet Online.